ライフサイエンスコーパス: hospitalisation

1 sociated with increased risk for involuntary hospitalisation.

2 e as the difference observed after a week of hospitalisation.

3 ther as a result of illness and particularly hospitalisation.

4 at high risk of venous thromboembolism after hospitalisation.

5 and 49 (24%; p=0.0087) died during neonatal hospitalisation.

6 suppression was only associated with reduced hospitalisation.

7 ed risk of long COVID diagnosis was COVID-19 hospitalisation.

8 ylaxis with standard doses of heparin during hospitalisation.

9 ime to cardiovascular death or heart failure hospitalisation.

10 ctiveness was 73% (48-85) against associated hospitalisation.

11 isk of de-novo ventricular arrhythmia during hospitalisation.

12 g received a macrolide antibiotic during the hospitalisation.

13 s not defined and often results in prolonged hospitalisation.

14 pring (21%) had at least 1 infection-related hospitalisation.

15 ion between area deprivation and involuntary hospitalisation.

16 were calculated for medication, surgery and hospitalisation.

17 the greatest risk of involuntary psychiatric hospitalisation.

18 associated with increased infection-related hospitalisation.

19 pment of interventions to reduce involuntary hospitalisation.

20 l interventions and long-term intensive care hospitalisations.

21 ounting for up to 30% of adult heart failure hospitalisations.

22 related illnesses were the leading causes of hospitalisations.

23 ased combined opioid-related and HCV-related hospitalisations.

24 and 67% (62-71) to prevent COVID-19-related hospitalisations.

25 ed with both a lower risk of alcohol-related hospitalisations (0.74, 0.71-0.77) and a lower risk of h

26 usted odds ratio 1.29, 95% CI 1.16-1.44) and hospitalisation (1.20, 1.15-1.26), but lower odds of mil

27 24-1.76; p<0.0001), and previous involuntary hospitalisation (2.17, 1.62-2.91; p<0.0001).

28 29 636 tests, 609 782 positive tests, 26 143 hospitalisations, 2432 ICU admissions, 9383 deaths, and

29 00 000 person-days) against COVID-19-related hospitalisation, 97.5% (97.1-97.8; 2.7 vs 0.2 per 100 00

30 underreporting of falls, fall injuries, and hospitalisations across both groups; and the relatively

31 order, were found for psychiatric inpatient hospitalisation (adjusted relative risk [aRR] = 2.0; 95%

32 ses in 2013, -78%, 95% CI -72 to -83) and in hospitalisation admissions (440 admissions in 2012 vs 14

33 is 13 billion euros, mainly accounted for by hospitalisation after fracture.

34 ns were noted in the age distribution of RSV hospitalisation among infants born in different months.

35 such care, patients require several weeks of hospitalisation and are vulnerable to secondary problems

36 photericin B administration requires patient hospitalisation and careful laboratory monitoring to ide

37 P) levels have been shown to predict risk of hospitalisation and death from COPD.

38 ccines maintains over 70% protection against hospitalisation and death in breakthrough confirmed omic

39 n mRNA vaccine was highly protective against hospitalisation and death in omicron cases (HR for hospi

40 Previous involuntary hospitalisation and diagnosis of a psychotic disorder we

41 lose temporal association with heart failure hospitalisation and heart failure mortality.

42 acute decompensated heart failure including hospitalisation and heart failure mortality.

43 Hospitalisation and mortality events were documented for

44 associations between involuntary psychiatric hospitalisation and perceived risk to others, positive s

45 reducing the delay between symptom onset and hospitalisation and rapid national and international res

46 We aimed to describe the duration of hospitalisation and safety of ambulatory management comp

47 sis of the relationships between involuntary hospitalisation and social context, clinical practice, a

48 f which 32 among 13 participants resulted in hospitalisation and were classified as serious adverse e

49 , or mean of both waves) with risk of falls, hospitalisations and all-cause mortality were assessed u

50 Fewer days were lost due to heart failure hospitalisations and cardiovascular death for patients a

51 s were the composite of total cardiovascular hospitalisations and cardiovascular death; cardiovascula

52 370 total cardiovascular hospitalisations and cardiovascular deaths occurred in t

53 uce the number and associated costs of child hospitalisations and clinical visits for acute diarrhoea

54 Three had severe disease with multiple hospitalisations and complications but responded promptl

55 food borne pathogen responsible for numerous hospitalisations and deaths all over the world.

56 (95% CI: 0.08, 0.20), P < 0.001 for malaria hospitalisations and deaths from malaria and 0.21 (95% C

57 well as overall country-specific patterns in hospitalisations and differences between countries in da

58 order with bridge prescriptions would reduce hospitalisations and overdose deaths by 3.2% and 3.6%, r

59 with addiction consult sevices would reduce hospitalisations and overdoses by 5.2% and 6.6%, respect

60 .9 mug/m(3) would prevent 7978 heart failure hospitalisations and save a third of a billion US dollar

61 s not associated with a reduction in overall hospitalisations and was associated with an increase in

62 ed cause-specific admission to hospital (ie, hospitalisation) and mortality, by age, sex, socioeconom

63 against severe or critical COVID-19-related hospitalisation, and 96.7% (96.0-97.3; 0.6 vs 0.1 per 10

64 ver-changing relationship between infection, hospitalisation, and death and hence provide vital infor

65 en and 16.9% in men resulted in death before hospitalisation, and hospital case fatality was 10.8% in

66 Absolute risk of mortality, hospitalisation, and MACE, at all levels of multimorbidi

67 ations with all-cause mortality, unscheduled hospitalisation, and major adverse cardiovascular events

68 d risk of adverse outcomes, including falls, hospitalisation, and mortality.

69 lness, reduced adherence to treatment before hospitalisation, and police involvement in admission.

70 533 624 HIV/AIDS-related hospitalisations, and 176 868 AIDS-related deaths had be

71 A total of 3 569 621 cases, 494 186 hospitalisations, and 99 954 deaths attributable to COVI

72 us gastroenteritis cases, outpatient visits, hospitalisations, and deaths between birth and 5 years,

73 Model parameters were inferred from past RSV hospitalisations, and forecasts made over a 10-year hori

74 utcomes were: total, elective, and emergency hospitalisations, and total and GP-referred specialist v

75 ainst respiratory syncytial virus-associated hospitalisations, and vaccine effectiveness was 81% (52-

76 es complications from abortion procedures or hospitalisation are rare.

77 populations at increased risk of involuntary hospitalisation are unclear, and evidence is needed to u

78 ripiprazole had similar rates of psychiatric hospitalisation as those prescribed olanzapine (adjusted

79 dpoint was the rate of heart-failure-related hospitalisations at 6 months.

80 tion could lead to a substantial increase in hospitalisation because of dengue.

81 f outpatient specialist visits and inpatient hospitalisations before and after the implementation of

82 We compared annual incidence of involuntary hospitalisation between 2008 and 2017 (where available)

83 ent, including all cardiovascular deaths and hospitalisations, between 1989 and 1995.

84 Although RSV hospitalisation burden mostly peaked at the second month

85 s 29%, p=0.017), reduced duration of initial hospitalisation, but higher risk of chronic myelogenous

86 er country experienced a change in trends in hospitalisations: change in slope for total, elective, a

87 had a 39% reduction in heart-failure-related hospitalisation compared with the control group (153 vs

88 icant reduction in the number of psychiatric hospitalisation contacts or treatment days.

89 Safe funeral practices and fast hospitalisation contributed to the containment of this E

90 Averted outpatient visits and hospitalisations could lead to treatment savings of appr

91 cohort study, we used national and regional hospitalisation data from 1968 to 2016 in England (Hospi

92 ember 31, 2015 using record-linked birth and hospitalisation data from Denmark, Scotland, England, an

93 The mean hospitalisation days per patient-year were 1.63 (SD 3.74

94 The primary outcome was the number of hospitalisation days per year.

95 CV disease and geographies there were fewer hospitalisations, diagnostic and interventional procedur

96 riven revascularisation and ischaemia-driven hospitalisation did not differ significantly between gro

97 ed prediction tool for estimating infant RSV hospitalisation distribution by birth month.

98 f susceptible individuals at higher risk for hospitalisation due to EVALI.

99 site outcome of cardiovascular mortality and hospitalisation due to heart failure compared with place

100 Annual increases in hospitalisation due to heart failure were 2.6% (1.9 to 3

101 h, self-harm, committing a violent crime, or hospitalisation due to interpersonal violence was 32.0%

102 r accidental death, violent criminality, and hospitalisation due to violence were more constant throu

103 ations (0.74, 0.71-0.77) and a lower risk of hospitalisations due to other substances except alcohol

104 nor was there a difference in the number of hospitalisations due to relapsing IBD during follow-up.

105 The median hospitalisation duration was 7 days (IQR 7-8).

106 roid dosing protocol to periods of prolonged hospitalisation during the first 3 postoperative months

107 CI, 10-45) lower risks of both infection and hospitalisation during the study period when the Delta v

108 nosis, reduced associations with psychiatric hospitalisations during beta-blocker treatment were main

109 uring follow-up 11.1-24.0% of patients had a hospitalisation/emergency room (ER) visit, median stay r

110 ation between depression and non-psychiatric hospitalisation episodes has never been researched in gr

111 gh with the largest direct cost driver being hospitalisations/ER visits.

112 1, 95% CI 2.20-3.09) for first mental health hospitalisation, followed by diabetes (1.93, 1.62-2.31),

113 on-fatal self-harm, violent criminality, and hospitalisation following violence, until Dec 31, 2015.

114 t use and non-elective CEA (performed during hospitalisation for a symptomatic ipsilateral stroke, tr

115 ce of major cardiovascular events (including hospitalisation for acute coronary syndrome, fatal myoca

116 l guidelines recommend colonoscopy following hospitalisation for acute diverticulitis.

117 ate the relative risks (RRs) and 95% CIs for hospitalisation for acute exacerbation of COPD associate

118 in pollutant concentration, RRs for same-day hospitalisation for acute exacerbation of COPD were 1.02

119 Patients were enrolled during hospitalisation for acute heart failure from 358 centres

120 h people with mental health problems) during hospitalisation for acute illness were analysed using a

121 Hospitalisation for adversity-related injury (violent, d

122 between intelligence and subsequent risk of hospitalisation for bipolar disorder in a prospective co

123 ite of time to death from any cause or first hospitalisation for cardiovascular reasons.

124 pation fails, the patient may need emergency hospitalisation for disimpaction.

125 tly lower in France, the UK and Germany, and hospitalisation for headache was significantly more freq

126 ovascular death (0.88 [0.77-1.00]) and first hospitalisation for heart failure (0.74 [0.67-0.83]).

127 mbined risk of cardiovascular death or first hospitalisation for heart failure (0.74, 0.68-0.82; p<0.

128 dial infarction (HR 0.84, 95% CI 0.75-0.95), hospitalisation for heart failure (0.83, 0.74-0.95), and

129 uced composite cardiovascular death or first hospitalisation for heart failure (hazard ratio 0.80 [95

130 er-estimated frequencies of cardiac death or hospitalisation for heart failure (the primary endpoint)

131 except demonstrating little or no effect on hospitalisation for heart failure and kidney failure.

132 wever, they have robust benefits on reducing hospitalisation for heart failure and progression of ren

133 imary combined endpoint was cardiac death or hospitalisation for heart failure at 12 months in the in

134 ld reduce the incidence of cardiac death and hospitalisation for heart failure at 12 months.

135 reduced the risk of cardiovascular death or hospitalisation for heart failure by 23% (0.77 [0.71-0.8

136 the combined risk of cardiovascular death or hospitalisation for heart failure in patients with heart

137 In men, the lowest hazards of death or hospitalisation for heart failure occurred at 100% of th

138 t ventricular (LV) systolic dysfunction, and hospitalisation for heart failure or intravenous drug th

139 improve clinical outcomes (cardiac death or hospitalisation for heart failure) at 12 months in patie

140 h), the composite of cardiovascular death or hospitalisation for heart failure, and progression of re

141 three primary (acute myocardial infarction, hospitalisation for heart failure, and stroke) and six s

142 on (NYHA) functional class, race, history of hospitalisation for heart failure, estimated glomerular

143 ease all-cause and cardiovascular mortality, hospitalisation for heart failure, kidney failure, non-f

144 the combined risk of cardiovascular death or hospitalisation for heart failure.

145 composite of time to all-cause mortality or hospitalisation for heart failure.

146 s of stroke, myocardial infarction (MI), and hospitalisation for heart failure; annual kidney disease

147 widen understanding for the global burden of hospitalisation for hypoglycaemia.

148 We aimed to investigate temporal patterns of hospitalisation for IBD in member countries of the Organ

149 bral malaria began to change 10 years before hospitalisation for malaria started to fall.

150 ere was no significant difference in risk of hospitalisation for mental health disorders between outf

151 The primary outcome was a composite of hospitalisation for non-fatal myocardial infarction or b

152 showing a significant and large reduction in hospitalisation for patients with NYHA class III heart f

153 er, nonliver, and all-cause mortality; first hospitalisation for severe liver morbidity (SLM); cardio

154 as coincided with an increase in acute adult hospitalisation for tonsillitis complications.

155 scular endpoint (which additionally included hospitalisation for unstable angina requiring unplanned

156 scular death, myocardial infarction, stroke, hospitalisation for unstable angina) occurred in 109 par

157 t non-fatal myocardial infarction or stroke, hospitalisation for unstable angina, arterial revascular

158 ntion of worsening chronic heart failure and hospitalisations for acute decompensation is also of gre

159 From Jan 18, 2013, to Dec 31, 2017, 161 613 hospitalisations for acute exacerbation of COPD were rec

160 were significantly associated with increased hospitalisations for acute exacerbations of COPD in Beij

161 were revisits to the emergency department or hospitalisations for bronchiolitis within 21 days of dis

162 s-old young woman with a history of multiple hospitalisations for foci of vascular anomalies appearin

163 e renal function, with greater reductions in hospitalisations for heart failure (p for interaction=0.

164 The primary outcome was a composite of total hospitalisations for heart failure and cardiovascular de

165 a 25% decrease in the composite of recurrent hospitalisations for heart failure or cardiovascular dea

166 ffects of empagliflozin and dapagliflozin on hospitalisations for heart failure were consistent in th

167 nvasive pneumococcal disease (IPD) and coded hospitalisations for non-invasive pneumococcal community

168 e, dysphagia and seizures are common, as are hospitalisations for pneumonia and urinary tract infecti

169 e show a significant increase (1.2%-267%) in hospitalisations for respiratory diseases in children un

170 Among 28 271 hospitalisations for respiratory syncytial virus-like il

171 Among 8435 hospitalisations for respiratory syncytial virus-like il

172 lion children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID

173 misphere vaccines were effective in reducing hospitalisations from influenza illness.

174 d neurological deficits following treatment, hospitalisation >5 days, overall morbidity and mortality

175 Rising annual incidence of involuntary hospitalisation have been reported in England and some o

176 d by 14% considering the general increase in hospitalisation; however, accounting for diabetes preval

177 iratory virus infection is a common cause of hospitalisation in adults.

178 on between birth by CS and infection-related hospitalisation in early childhood.

179 ode of birth and childhood infection-related hospitalisation in high-income countries with varying CS

180 mic monitoring systems might reduce rates of hospitalisation in patients with heart failure.

181 had no association with first mental health hospitalisation in this subgroup.

182 Since most child pneumonia hospitalisations in Africa occur in non-tertiary distric

183 Aerosol was the primary driver of hospitalisations in drought affected municipalities duri

184 (R-UTIs) are the main cause of morbidity and hospitalisations in subjects with neurogenic bladder (NB

185 of an association between annual involuntary hospitalisation incidence and any other demographic, eco

186 thorax significantly reduced the duration of hospitalisation including re-admissions in the first 30

187 Age-adjusted first-year rates of hospitalisation increased by 28% for all-cause admission

188 g that reduced funeral attendance and faster hospitalisation independently influenced local transmiss

189 ich safe burials are increased and effective hospitalisation instituted under two scenarios: (i) one

190 We find that a 50% reduction in RSV hospitalisations is possible if the maternal vaccine eff

191 In the scenario with low hospitalisation levels (cost per DALY averted $690, 143

192 was also the case for the scenario with high hospitalisation levels (cost per DALY averted -$512, 95%

193 tional Health Service (NHS) and maintain low hospitalisation levels.

194 After exclusion of patients with a length of hospitalisation longer than 3 days or heart disease, the

195 d old age is associated with non-psychiatric hospitalisation, longer length of stay and higher mortal

196 eight were serious adverse events requiring hospitalisation mainly due to diarrhoeal disease (one [1

197 (vs a baseline scenario of 3 weeks) reduced hospitalisations, mortality, and restrictions for vaccin

198 Serious adverse reactions necessitating hospitalisation occurred in 33 infants (16 on hormonal t

199 217 total heart failure hospitalisations occurred in the ferric carboxymaltose g

200 evel associated with involuntary psychiatric hospitalisation of adults.

201 t under the scenarios of different levels of hospitalisation of dengue cases (low [25%], medium [50%]

202 uneral contacts: severe symptoms, death, non-hospitalisation, older age, and travelling prior to symp

203 The composite of first heart failure hospitalisation or cardiovascular death occurred in 181

204 The primary endpoint was cardiovascular hospitalisation or cardiovascular death, with a hazard r

205 ospitalisations; time to first heart failure hospitalisation or cardiovascular death; and days lost d

206 entration were associated with heart failure hospitalisation or death (PM2.5 2.12% per 10 mug/m(3), 9

207 es were associated with an increased risk of hospitalisation or death from falls (adjusted hazard rat

208 Heart failure hospitalisation or death was associated with increases i

209 For the incidence (hospitalisation or death) rates of specific diseases, RR

210 ed to examine a 1-year composite outcome (HF hospitalisation or mortality).

211 ed to a different treatment model because of hospitalisation or travel (58 patients), leaving 4,173 T

212 ar death; and days lost due to heart failure hospitalisations or cardiovascular death, all evaluated

213 and high adherence to SMC, the incidence of hospitalisations or deaths due to malaria and uncomplica

214 y outcomes between groups: ED presentations, hospitalisations or falls risk, falls efficacy, and qual

215 um [PM10]) air pollutants, and heart failure hospitalisations or heart failure mortality.

216 anders for publicly funded events, including hospitalisation, outpatient, pharmaceutical, laboratory

217 f various policy scenarios on infections and hospitalisations over 200 days.

218 efit was associated with a lower risk of SUD hospitalisations overall (incidence rate ratios [IRR] 0.

219 Infection-related hospitalisations (overall and by clinical type) occurrin

220 ociated with revisits (p=0.55) or subsequent hospitalisations (p=0.50).

221 icantly more episodes and longer duration of hospitalisation, particularly those due to cancer and re

222 After additional adjustment for prior hospitalisation, patients prescribed aripiprazole had si

223 chiatric disorders and psychiatric inpatient hospitalisation, premature mortality (before age 41 y),

224 1 year, they had higher RSV-associated ALRI hospitalisation rate in the first 6 months (RR 1.93 [1.1

225 For example, Turkey had an annual hospitalisation rate of 10.8 per 100 000 inhabitants and

226 Similarly, Chile had an annual hospitalisation rate of 9.0 per 100 000 inhabitants and

227 The annual hospitalisation rate varies from a low of about 3 per 10

228 , the RSV-associated ALRI incidence rate and hospitalisation rate were significantly higher (rate rat

229 Acute seizure-related hospitalisations (rate ratio [RR] 0.43 [95% CI 0.20-0.94

230 m the OECD database, we assessed IBD-related hospitalisation rates (expressed as annual rates per 100

231 d no relationship between annual involuntary hospitalisation rates and any characteristics of the leg

232 e extent of variations in involuntary annual hospitalisation rates between countries, to compare tren

233 and the Caribbean had the lowest IBD-related hospitalisation rates but the greatest increases in rate

234 locker treatment were mainly driven by lower hospitalisation rates due to depressive (HR: 0.92, 95% C

235 ve/torrential -5.8% [-17.6, 6.0], whereas HF hospitalisation rates favoured TTVR in the massive/torre

236 Hospitalisation rates for IBD are high in western countr

237 Mean hospitalisation rates for IBD from 2010 to 2015 were hig

238 Hospitalisation rates for IBD were stabilising or decrea

239 Hospitalisation rates for inflammatory bowel disease (IB

240 We calculated mean hospitalisation rates for the period 2010-15 and used jo

241 oeconomic, lifestyle, and morbidity factors, hospitalisation rates increased annually by 3.6% for str

242 We estimated incidence and hospitalisation rates of influenza-virus-associated resp

243 ith HIV in Europe and 9612 in North America, hospitalisation rates per 100 person-years were 16.2 (95

244 Understanding why involuntary hospitalisation rates vary so much could be advanced thr

245 evidence for decreased acute chest syndrome, hospitalisation rates, and transfusion.

246 Higher socioeconomic groups had higher hospitalisation rates, but the annual proportional incre

247 peared to be unrelated to annual involuntary hospitalisation rates.

248 ased combined opioid-related and HCV-related hospitalisation rates.

249 be associated with variations in involuntary hospitalisation rates.

250 on if infected) using age-specific infection-hospitalisation ratios for COVID-19 estimated for mainla

251 ces, multimorbidity fractions, and infection-hospitalisation ratios, and plausible low and high estim

252 There was evidence that hospitalisation reduced but did not eliminate onward exp

253 erioration for PRO variables of interest and hospitalisation-related endpoints.

254 uces overdose risk and recurrent infections, hospitalisation remains common.

255 proportion of patients who had non-elective hospitalisation (respiratory and all-cause) and acute ex

256 ptible to the effects of these pollutants on hospitalisation risk than were men and patients younger

257 of onset, and the use of antidepressants in hospitalisation risk.

258 scular events, 2028 cardiovascular deaths or hospitalisation sfor heart failure events, and 766 renal

259 over a short time interval (within the same hospitalisation) significantly worsened renal function i

260 sequelae; and (iii) compare sequelae risk by hospitalisation status and pathogen.

261 We found that district, hospitalisation status, age, case classification and qua

262 We found that district, hospitalisation status, age, case classification, and qu

263 Mean expenditures for surgeries and hospitalisation tended to be lower in the transition gro

264 uropean countries, but less likely to report hospitalisation than in Canada and Australia.

265 the base-case scenario of moderate level of hospitalisation, the CIMIC programme was cost-saving wit

266 The combination of mask use with reduced hospitalisation time and a shift to outpatient therapy c

267 h; cardiovascular death; total heart failure hospitalisations; time to first heart failure hospitalis

268 und a higher annual incidence of involuntary hospitalisation to be associated with a lower rate of ab

269 Use of involuntary psychiatric hospitalisation varies widely within and between countri

270 The median rate of involuntary hospitalisation was 106.4 (IQR 58.5 to 150.9) per 100 00

271 Involuntary rather than voluntary hospitalisation was associated with male gender (odds ra

272 A significantly higher risk of all-cause hospitalisation was found for the most deprived than for

273 Adjusted incidence of hospitalisation was high across sites, and overall, 2804

274 The relative rate-ratio of hospitalisation was highest at <1-hour travel time for S

275 At day 30, the median hospitalisation was significantly shorter in the 114 pat

276 incidence rate ratio for repeat ED visits or hospitalisations was 0.89 (95% CI, 0.86 to 0.93) for sei

277 e, the adjusted IRR was 0.68 (0.62-0.74) for hospitalisation, was 0.54 (0.43-0.70) for ICU admission,

278 Higher national rates of involuntary hospitalisation were associated with a larger number of

279 ts diagnosed prior to or up to 30 days after hospitalisation were defined as prevalent diabetes and w

280 No serious adverse events requiring hospitalisation were reported after immunisation.

281 in slope for total, elective, and emergency hospitalisations were -0.2% (95% CI -0.6%-0.2%; p = 0.25

282 167 641 (73%) of 228 113 hospitalisations were for non-cardiovascular causes and

283 vaccination records, IPD notifications, and hospitalisations were individually linked for children a

284 In 6 months, 83 heart-failure-related hospitalisations were reported in the treatment group (n

285 of 1.43 (1.17-1.74) for first mental health hospitalisation, whereas epilepsy (1.33, 0.70-2.52) and

286 ence of peripheral artery disease (including hospitalisation with a diagnosis of peripheral artery di

287 Risk of hospitalisation with any form of bipolar disorder fell i

288 ed, was associated with an increased risk of hospitalisation with asthma but no difference in risk of

289 Risk of hospitalisation with asthma was greater following both u

290 tcomes assessed included obesity at age 5 y, hospitalisation with asthma, learning disability, cerebr

291 ve LFIA is associated with increased risk of hospitalisation with COVID-19 (HR: 2.73 [95% confidence

292 dentified during follow-up colonoscopy after hospitalisation with CT-proven left-sided diverticulitis

293 ovided moderate long-term protection against hospitalisation with PPV23 serotype pneumonia.

294 Hospitalisations with a discharge diagnosis of an acute

295 An additional 12 (95%CI 0-23) hospitalisations with epilepsy and 4 (95%CI 0-6) with de

296 s safe and reduced the risk of heart failure hospitalisations, with no apparent effect on the risk of

297 ere generally followed by a similar trend in hospitalisations within 7 days and deaths within 15 days

298 ate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients wi

299 driven revascularisation or ischaemia-driven hospitalisation without revascularisation.

300 outcomes: number of febrile UTIs, number of hospitalisations, WOCA tolerance, antibiotic consumption